All posts by: Michael Zand

About Michael Zand

British Biotech Pockets Massive Series C for its CAR-T Cancer Therapies – Labiotech.eu (blog)

Continue reading

2017-09-26 NEWS

British Biotech Pockets Massive Series C for its CART Cancer Therapies
Labiotech.eu (blog)
Autolus, based in London, has raised €68M in Series C to continue developing its T cell immunotherapies for cancer treatment. Autolus focuses on developing engineered T cell immunotherapies to beat cancer. Its pipeline includes therapies targeted at

Continue reading

2017-09-26 NEWS

British Biotech Pockets Massive Series C for its CART Cancer Therapies
Labiotech.eu (blog)
Autolus, based in London, has raised €68M in Series C to continue developing its T cell immunotherapies for cancer treatment. Autolus focuses on developing engineered T cell immunotherapies to beat cancer. Its pipeline includes therapies targeted at

Continue reading

2017-09-26 NEWS

Phys.Org

A ‘social control’ system guarantees embryonic stem cell purity
Phys.Org
A sophisticated system of “social control” operating between neighboring cells allows embryos to protect the purity of their pluripotent cell population, which is able to generate all body tissues. This system works through the elimination of cells

Continue reading

2017-09-26 NEWS

MEDICAL Q&A: Cancer immunotherapy revolution is just beginning
Sarasota Herald-Tribune
Q: Will the new methods of immunotherapy against cancer become the standard for treatment? A: In the fight against cancer, research is moving so fast that today’s breakthroughs can easily become tomorrow’s has-beens. Novartis recently got approval for